Investigational drug · Phase 2
Pegenzileukin
Also called: SAR444245
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Plasma Cell Myeloma Refractory.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "Pegenzileukin"
First trial start
2021
Jan 25, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Pegenzileukin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Plasma Cell Myeloma Refractory
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Pegenzileukin" as an intervention, largest first.
- Isatuximab in Combination With Novel Agents in RRMM - Master ProtocolPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT04643002 · 258 participants (planned) · Start Jan 25, 2021 · Primary completion Sep 13, 2027
Drug: Isatuximab; Dexamethasone and 6 more · For: Plasma Cell Myeloma Refractory
Sites: Birmingham, Alabama; Atlanta, Georgia; Chicago, Illinois · 28 sites in all
Synthorx, Inc, a Sanofi companyIndustry
NCT04009681 · 175 participants · Start Jun 20, 2019 · Primary completion Dec 2, 2025
Drug: THOR-707; Checkpoint inhibitor and 1 more · For: Metastasis
Sites: Scottsdale, Arizona; Denver, Colorado; Sarasota, Florida · 24 sites in all
SanofiSanofi (SNY)
NCT05104567 · 138 participants · Start Dec 9, 2021 · Primary completion Jul 26, 2023
Drug: THOR-707; Pembrolizumab and 1 more · For: Oesophageal Squamous Cell Carcinoma; Gastric Cancer; Hepatocellular Carcinoma and 2 more
Sites: Duarte, California; Orlando, Florida; Seattle, Washington · 29 sites in all
SanofiSanofi (SNY)
NCT04914897 · 106 participants · Start Sep 23, 2021 · Primary completion Jul 18, 2023
Drug: THOR-707; Pembrolizumab · For: Pleural Mesothelioma; Non-small Cell Lung Cancer
Sites: Philadelphia, Pennsylvania; CABA, Argentina; Richmond, Australia · 35 sites in all
SanofiSanofi (SNY)
NCT05179603 · 14 participants · Start Dec 7, 2021 · Primary completion Sep 14, 2023
Drug: THOR-707; Pembrolizumab · For: Classic Hodgkin Lymphoma; Diffuse Large B-cell Lymphoma
Sites: CABA, Argentina; Santiago, Chile; Viña del Mar, Chile · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- CD8 T-cell exhaustion linked with CAR T-cell failure can be mitigated by a non-alpha IL2 receptor agonist.
Arita K, Dai E, Li X, et al. · Blood 2026
- Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study.
Harris WP, García-Alfonso P, Metges JP, et al. · Invest New Drugs 2026
- Phase 1/2 study of pegenzileukin, a pegylated recombinant non-alpha IL-2, with cemiplimab for the treatment of advanced unresectable or metastatic skin cancers.
Rojas C, Mortier L, Park JJ, et al. · J Immunother Cancer 2026
- SAR-444245, an engineered not-alpha IL-2 leveraging synthetic biology, modulates critical components of the immune system for durable anti-tumoral activity.
Ma L, Acuff NV, Ptacin JL, et al. · J Immunol 2025
- A Precision Engineered Interleukin-2 for Bolstering CD8+ T- and NK-cell Activity without Eosinophilia and Vascular Leak Syndrome in Nonhuman Primates.
Ma L, Acuff NV, Joseph IB, et al. · Cancer Res Commun 2024
Also in development for Plasma Cell Myeloma Refractory
- EvorpaceptALX148Phase 25 trials
ALX Oncology Inc. · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Metastatic
- SAR439459Phase 21 trial
Sanofi · Plasma Cell Myeloma Refractory
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.